23時間前 -Multiple myeloma (MM) is a plasma cell disorder accounting for approximately 10% of hematologic malignancies. There is limited epidemiological evidence ...
19時間前 -Myeloma cells express Toll-like receptors (TLRs), and TLR activation has been shown to induce proliferative and pro-survival signals in cancer cells. MM is a ...
16時間前 -Linvoseltamab demonstrated durable efficacy with a manageable safety profile in patients with relapsed/refractory multiple myeloma.
7時間前 -Vicki Jones shares her 20-year journey with multiple myeloma, highlighting resilience, support, and advanced treatments. An inspiring journey of hope.
16時間前 -... multiple myeloma. The MRD2STOP trial, presented at ASCO Annual Meeting, observed multiple factors in patients to determine the discontinuation of ...
... multiple myeloma. David Samuel Dicapua Siegel, MD, chief, Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center ...
YouTube-OncLive
12時間前 -Recent phase III findings support the antibody-drug conjugate belantamab mafodotin-blmf as a treatment option for patients with multiple myeloma in early ...
16時間前 -Treatment with linvoseltamab (REGN5458) led to deep and durable responses in patients with relapsed/refractory multiple myeloma, according to findings from ...
16時間前 -Commenting specifically on the DREAMM-8 trial, Dr. Odejide said BPd “is poised to be a potential new treatment strategy for relapsed-refractory multiple myeloma ...
15時間前 -Multiple Myeloma Informational Booklets: Download myeloma educational publications created by the International Myeloma Foundation. Download IMF ...
